Autologous Cell Therapy Global Market Report 2024

The autologous cell therapy market has grown rapidly in recent years. It will grow from $8.58 billion in 2023 to $10.22 billion in 2024 at a compound annual growth rate (CAGR) of 19.2%. During the historical period, growth can be primarily attributed to several factors. These include advancements within regenerative medicine, the rising prevalence of chronic diseases prompting the exploration of alternative treatments, improved comprehension of cellular biology, a growing preference among patients for personalized medicine, and significant clinical successes leading to positive outcomes in treatment methodologies.

The autologous cell therapy market is expected to see rapid growth in the next few years. It will grow to $19.53 billion in 2028 at a compound annual growth rate (CAGR) of 17.6%. Anticipated growth in the forecast period is expected due to several key factors. These encompass the sustained expansion of regenerative medicine, the broadening scope of applications across diverse medical specialties, advancements in cell culture techniques, escalating investments and intensified research initiatives, as well as robust regulatory support and the establishment of standardized practices. Key trends projected for this period involve the development of automated manufacturing technologies to streamline processes, the integration of biomarkers into treatment strategies for enhanced efficacy, the emergence of point-of-care cell processing methods, the widening application beyond hematopoietic stem cells, and an increase in collaborative efforts and partnerships within the industry to foster innovation and progress.

The burgeoning prevalence of chronic diseases is poised to fuel the expansion of autologous cell therapy. Chronic diseases, persisting for more than a year, necessitate continual medical attention. Autologous cell therapy, leveraging an individual's cultivated and amplified cells reintroduced into the donor, holds promise in managing and treating such conditions. According to the National Library of Medicine's January 2023 report, the US is projected to witness 142.66 million people aged 50 and above with at least one chronic condition by 2050. Hence, the heightened prevalence of chronic diseases propels the growth of the autologous cell therapy market.

The escalating aging population is anticipated to drive the growth of the autologous cell therapy market. The aging population, characterized by rising median age and extended life expectancy, stands to benefit from autologous cell therapies due to their potential for tailored and personalized interventions. As projected by the ARC Centre of Excellence in Population Ageing Research, Australia's population aged 65 and above is estimated to surge from 4.31 million in 2021 to 6.66 million by 2041, an impressive 54% increase. Thus, the burgeoning aging demographic fuels the expansion of the autologous cell therapy market.

Technological advancements emerge as a prominent trend shaping the autologous cell therapy market. Market leaders are automating the process to enhance efficiency and ensure sustainability. Lonza, for instance, unveiled the Cocoon Platform in April 2022, a cutting-edge technology streamlining personalized cell and gene therapy manufacturing. This platform, driven by an automated closed system, minimizes contamination risk, upholds manufacturing sterility, substantially bolsters quality, reduces labor and material expenses, and facilitates the scalable production of autologous T-cell products.

Major players in the autologous cell therapy realm are forging strategic partnerships and collaborations to fortify their market positions. Strategic partnerships, fostering collaborative endeavors between multiple entities, aim to achieve specific business objectives. Notably, in March 2022, Novartis inked an initial agreement with Carisma Therapeutics, aiming to manufacture HER 2 targeted CAR-M cell therapy. The collaboration involves transferring Carisma Therapeutics' manufacturing process to Novartis' Cell Therapy Site in the US, scheduling clinical manufacturing to commence in 2023, focusing on treating solid tumors in initial trials.

In October 2023, Clade Therapeutics, a US-based cell therapy company, successfully acquired Gadeta B.V. for an undisclosed sum. This strategic acquisition significantly enriches Clade's repertoire by incorporating innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies tailored for cancer patients into its existing portfolio. Gadeta B.V., based in the Netherlands, specializes in the development of cell therapies.

Major companies operating in the autologous cell therapy market report are Bristol-Myers Squibb Company, Novartis AG, Vericel Corporation, Holostem Terapie Avanzate S.r.l., Pharmicell Co. Ltd., Opexa Therapeutics Inc., Tego Science AB, Brainstorm Cell Therapeutics Inc., Caladrius Biosciences Inc., Lineage Cell Therapeutics Inc., Castle Creek Biosciences Inc., Gilead Sciences Inc., Johnson & Johnson, CORESTEM Inc., Dendreon Pharmaceuticals LLC, Medipost Co. Ltd., PharmaJet Inc., Bioject Medical Technologies Inc., Medical International Technology Inc., INJEX Pharma AG, Lonza Group Ltd., Corning Incorporated, Takeda Pharmaceutical Company Limited, CSL Limited, AstraZeneca plc, Moderna Inc., Sinovac Biotech Ltd., Valneva SE, Bavarian Nordic A/S, Dynavax Technologies Corporation.

North America was the largest region in the autologous cell therapy market in 2023. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autologous cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Within autologous cell therapy, two primary types are prevalent, autologous stem cell therapy and autologous cellular immunotherapies. Autologous stem cell therapy, a specific facet of this therapy, harnesses stem cells sourced from the patient's own body for therapeutic purposes. These stem cells are derived from various sources such as bone marrow, epidermis, mesenchymal stem cells, hematopoietic stem cells, chondrocytes, among others. Their applications span across a wide spectrum of medical areas, including cancer, neurodegenerative disorders, cardiovascular issues, autoimmune conditions, orthopedics, and wound healing. This therapy finds application across multiple sectors including hospitals, clinics, ambulatory centers, academic and research institutions, and other healthcare settings, serving as a versatile approach in addressing various health challenges.

The autologous cell therapy market research report provides autologous cell therapy market statistics, including autologous cell therapy industry global market size, regional shares, competitors with a autologous cell therapy market share, detailed autologous cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the autologous cell therapy industry. This autologous cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The autologous cell therapy market includes revenues earned by providing services in relation to cell collection, cell processing, cell expansion, or its modification. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.